ERBB2 and breast cancer: Thus, in agreement with the 2007 and 2009 American Society of Clinical Oncology guidelines on the use of biomarkers in breast cancer [11,13], there is currently insufficient evidence to support the use of serum HER-2 ECD in the routine management of individual patients with breast cancer.